Ciccarese, Chiara
 Distribuzione geografica
Continente #
EU - Europa 2.698
NA - Nord America 2.439
AS - Asia 1.884
SA - Sud America 246
AF - Africa 71
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 7.344
Nazione #
US - Stati Uniti d'America 2.371
RU - Federazione Russa 1.050
SG - Singapore 690
GB - Regno Unito 651
CN - Cina 614
IT - Italia 246
BR - Brasile 183
SE - Svezia 182
VN - Vietnam 175
IE - Irlanda 147
HK - Hong Kong 143
DE - Germania 126
FR - Francia 113
KR - Corea 58
FI - Finlandia 53
IN - India 36
CA - Canada 31
AR - Argentina 29
BD - Bangladesh 27
MX - Messico 27
NL - Olanda 25
PL - Polonia 25
TR - Turchia 23
JP - Giappone 21
NG - Nigeria 20
ID - Indonesia 18
ZA - Sudafrica 15
ES - Italia 13
UA - Ucraina 13
EC - Ecuador 12
IQ - Iraq 12
MA - Marocco 11
BE - Belgio 9
AT - Austria 7
LT - Lituania 7
PH - Filippine 7
PK - Pakistan 7
VE - Venezuela 7
AZ - Azerbaigian 6
MY - Malesia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
KE - Kenya 5
PY - Paraguay 5
CH - Svizzera 4
EU - Europa 4
SA - Arabia Saudita 4
AL - Albania 3
CL - Cile 3
CO - Colombia 3
EG - Egitto 3
GR - Grecia 3
JO - Giordania 3
LK - Sri Lanka 3
RO - Romania 3
SN - Senegal 3
TH - Thailandia 3
TN - Tunisia 3
BG - Bulgaria 2
CR - Costa Rica 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LY - Libia 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TG - Togo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GH - Ghana 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MW - Malawi 1
NE - Niger 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SO - Somalia 1
Totale 7.340
Città #
Southend 609
Moscow 356
Singapore 356
Ashburn 319
Chandler 300
San Jose 246
Dallas 172
Dublin 147
Beijing 144
Hong Kong 142
Woodbridge 105
The Dalles 98
Ann Arbor 74
Verona 74
Los Angeles 65
Houston 60
New York 58
Ho Chi Minh City 48
Lawrence 46
Princeton 46
Jacksonville 44
Nanjing 42
Wilmington 38
Hanoi 31
Jinan 31
São Paulo 31
Shenyang 26
Santa Clara 24
Montreal 21
Abuja 20
Redondo Beach 20
Columbus 19
Hebei 19
Buffalo 18
Denver 17
Munich 17
Tokyo 17
Helsinki 16
Tianjin 16
Changsha 15
Brooklyn 14
Redwood City 14
Dong Ket 13
Guangzhou 13
Haikou 13
Milan 13
Sindelfingen 13
Zhengzhou 13
Stockholm 12
Warsaw 12
Johannesburg 11
Jakarta 10
London 10
Mexico City 10
Orem 10
Seoul 10
Taizhou 10
Amsterdam 9
Da Nang 9
Frankfurt am Main 9
Jiaxing 9
Bologna 8
Brussels 8
Council Bluffs 8
Dearborn 8
Ningbo 8
Norwalk 8
Biên Hòa 7
Boston 7
Chennai 7
Dhaka 7
Fuzhou 7
Kent 7
Nanchang 7
Rome 7
Seattle 7
Vienna 7
Ankara 6
Baku 6
Campinas 6
Hangzhou 6
Lanzhou 6
Phoenix 6
Taiyuan 6
Tashkent 6
Turku 6
Chicago 5
Haiphong 5
Istanbul 5
Krakow 5
New Delhi 5
Paris 5
San Francisco 5
Atlanta 4
Bussolengo 4
Casablanca 4
Catanzaro 4
Fairfield 4
Falkenstein 4
Groningen 4
Totale 4.419
Nome #
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 247
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 229
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 214
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 209
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 199
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 198
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 196
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 194
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 191
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 186
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 185
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 185
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 185
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 182
AR-V7 and prostate cancer: The watershed for treatment selection? 178
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 177
The development of PARP as a successful target for cancer therapy 175
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 174
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 173
2015 and human cancer: back to overall survival 168
The route to personalized medicine in bladder cancer: where do we stand? 162
Metabolic phenotype of bladder cancer 162
Metabolic alterations in renal cell carcinoma 160
Inside the 2015 ASCO Genitourinary Cancers Symposium 155
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 154
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer 150
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 149
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer 149
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 149
Metabolic Alterations in Renal and Prostate Cancer 146
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 146
Bladder cancer: molecular determinants of personalized therapy 145
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 139
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma 138
Acquired hemophagocytic syndrome: comment to the case report 136
Kidney cancer and 2014: is innovation really over? 128
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 128
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR? 126
Emerging Immunotargets in Bladder Cancer 126
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 122
Role of STAT3 pathway in genitourinary tumors 109
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 104
Tp53 and its potential therapeutic role as a target in bladder cancer 102
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 99
The prospect of precision therapy for renal cell carcinoma 86
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer 77
Present and future of personalized medicine in adult genitourinary tumors 73
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 60
Totale 7.425
Categoria #
all - tutte 23.881
article - articoli 23.881
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.762


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202152 0 0 0 0 0 0 0 0 0 7 20 25
2021/2022282 15 66 2 32 23 8 3 21 10 8 11 83
2022/2023827 54 96 72 136 59 221 2 62 93 11 17 4
2023/2024357 13 34 25 32 75 36 10 39 5 18 60 10
2024/20251.019 48 54 51 234 27 37 23 20 199 47 87 192
2025/20263.364 220 162 212 707 898 216 266 163 316 204 0 0
Totale 7.425